Allarity Therapeutics
ALLR
4 hedge funds and large institutions have $46.2K invested in Allarity Therapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, reducing their positions, and 6 closing their positions.
1.48% more ownership
Funds ownership: 0.07% → 1.55% (+1.5%)
56% less funds holding
Funds holding: 9 → 4 (-5)
57% less capital invested
Capital invested by funds: $108K → $46.2K (-$61.6K)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$80.2K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$14.1K |
| 3 |
DB
Danske Bank
Copenhagen K,
Denmark
|
+$38 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$28 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$56K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$21.8K |
| 3 |
JF
Jump Financial
Chicago,
Illinois
|
-$8.26K |
| 4 |
HF
HRT Financial
New York
|
-$7K |
| 5 |
Jane Street
New York
|
-$3.33K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $38.9K | +$80.2K | +17,078 | +1,243% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $7.18K | +$14.1K | +2,998 | +740% |
|
|
3
Bank of America
Charlotte,
North Carolina
| $23 | +$28 | +6 | +120% |
|
|
DB
4
Danske Bank
Copenhagen K,
Denmark
| $17 | +$38 | +8 | New |
|
|
VF
5
Virtu Financial
New York
| – | -$56K | -8,845 | Closed |
|
|
6
Geode Capital Management
Boston,
Massachusetts
| – | -$21.8K | -3,411 | Closed |
|
|
JF
7
Jump Financial
Chicago,
Illinois
| – | -$8.26K | -1,293 | Closed |
|
|
HF
8
HRT Financial
New York
| – | -$7K | -1,156 | Closed |
|
|
9
Jane Street
New York
| – | -$3.33K | -522 | Closed |
|
|
HT
10
Headlands Technologies
Chicago,
Illinois
| – | -$4 | -1 | Closed |
|
ALLR Hedge Fund Activity: Q3 2024 in Review
4 of the 6,970 institutional investors tracked by Wall St. Rank reported a position in Allarity Therapeutics (ALLR) for Q3 2024, worth a combined $46.2K — down 57% from $108K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ALLR and 1 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 3 added.
The largest buyer was UBS Group, adding an estimated $80.2K. The largest seller was Virtu Financial, exiting entirely with an estimated $56K sold.
- 4 institutional investors held Allarity Therapeutics (ALLR) as of Q3 2024, down from 9 in Q2 2024.
- Funds reported $46.2K of Allarity Therapeutics stock for Q3 2024, down 57% quarter-over-quarter.
- 1 fund opened new Allarity Therapeutics positions in Q3 2024 and 6 closed out, a net change of -5 holders.
- The largest Allarity Therapeutics buyer in Q3 2024 was UBS Group, an estimated $80.2K added.
- The largest Allarity Therapeutics seller in Q3 2024 was Virtu Financial, an estimated $56K sold.
Based on aggregated 13F filings for Q3 2024.